# Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Source: https://onco.cc/trials/nct01993810/  
OnCo record `nct01993810` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of carboplatin, cisplatin, durvalumab, etoposide and other drugs in lung cancer, run by Radiation Therapy Oncology Group, active but no longer recruiting.

## Summary

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer is a phase 3, randomised interventional study registered as NCT01993810 by Radiation Therapy Oncology Group, with a registry enrolment figure of 330 participants, started 2014-01-03 and due to reach its primary completion in 2028-11-30. Interventions recorded: Carboplatin; Cisplatin; Durvalumab; Etoposide; Paclitaxel; Pemetrexed Disodium; Photon Beam Radiation Therapy; Proton Beam Radiation Therapy; Quality-of-Life Assessment; Questionnaire Administration. Conditions listed: Stage II Non-Small Cell Lung Cancer AJCC v7; Stage IIA Non-Small Cell Lung Carcinoma AJCC v7; Stage IIB Non-Small Cell Lung Carcinoma AJCC v7; Stage III Non-Small Cell Lung Cancer AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7; Stage IIIB Non. Primary outcome: Overall Survival. Lung eligibility wording from the registry: "* Histologically or cytologically proven diagnosis of non-small cell lung cancer". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT01993810
- Phase: 3
- Setting: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
- Sponsor: Radiation Therapy Oncology Group
- Enrolled: 330

## Sources

- ClinicalTrials.gov NCT01993810: https://clinicaltrials.gov/study/NCT01993810

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/), [Proton therapy](https://onco.cc/technologies/proton-therapy/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Etoposide](https://onco.cc/drugs/etoposide/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [NRG Oncology](https://onco.cc/companies/nrg-oncology/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct01993810.json